Money · Lobbying reports · 119th Congress
S. 5316
7 saved lobbying reports name S. 5316.
7 reports
Confirmed from the official recordSenate Office of Public Records cannot vouch for the data or analyses derived from these data after the data have been retrieved from LDA.gov.
Lobbying Disclosure Act reports, LDA.gov. This copy was read November 22, 2026 at 12:39 PM Eastern.
Reports that name this bill
The amount is what the report gives for the whole quarter: everything the registrant did for that client, all issues together. A linked name opens that organization’s page on this site.
| Registrant | Client | Amount for the whole quarter | Quarter | Filed | Report |
|---|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $7,040,000.00reported as expenses | July to September 2026 | Open the report | |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $1,530,000.00reported as expenses | July to September 2026 | Open the report | |
| NOVARTIS | NOVARTIS | $840,000.00reported as expenses | July to September 2026 | Open the report | |
| SACHEM STRATEGIES | STRAND THERAPEUTICS | $20,000.00reported as income | July to September 2026 | Open the report | |
| FDD ACTION | FDD ACTION | $210,000.00reported as expenses | July to September 2026 | Open the report | |
| ALSTON & BIRD LLP | CURIE BIO OPERATIONS, LLC | $150,000.00reported as income | July to September 2026 | Open the report | |
| DLA PIPER LLP (US) | NOVARTIS | $60,000.00reported as income | July to September 2026 | Open the report |